SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending as traders discuss its potential as a crypto treasury play following news of a $300M private placement, with community members comparing it to previous runners like $QMMM. Bullish sentiment is fueled by the company's plans to rebrand as Solmate and focus on Solana-based digital assets, while others caution about potential dilution and the sustainability of the rally. The stock's low float and volatile price action are also driving considerable conversation.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

LEN is trending due to a mixed earnings report, with community members debating whether increased orders offset squeezed margins. Discussions also focus on lowered guidance and the potential impact of interest rate cuts on the housing market. The stock's price movement and future commentary from the company are key points of interest for investors.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx ($FDX) is trending following its Q1 earnings release, which featured a better-than-expected EPS and revenue. Despite the earnings beat, the stock dipped in after-hours trading as community members discuss the company's soft guidance and concerns around global trade and tariffs. Some traders are speculating about a potential short squeeze and monitoring the upcoming conference call for further insights.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending due to a boycott spurred by the reported suspension of Jimmy Kimmel from ABC, generating heated debate about free speech and political bias. The community is divided, with some supporting the boycott and others arguing it's an overreaction or politically motivated. Broader concerns around Disney's content and business decisions are also being discussed alongside the immediate controversy.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the potential impact of FedEx's earnings and broader concerns about shipping volumes and costs. Community discussions revolve around the stock's high dividend yield and whether it can be sustained, along with speculation about a potential bottom and future price targets. Some traders are also discussing the impact of US-China trade tensions on shipping demand for UPS.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amid discussions around Panasonic's anode-free solid-state battery announcement, with investors speculating about a potential partnership with QS and Tesla. The community is analyzing patent landscapes and commercialization timelines, debating whether this signals validation or competition for QS's technology. Bullish sentiment suggests a possible breakthrough for solid-state batteries, while bears caution about execution risks and insider selling.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares

SOXS is trending as traders discuss potential catalysts for a semiconductor sector downturn, including US-China relations and profit-taking on tech stocks. Community members are debating entry points, with some bracing for further declines and others anticipating a bounce. The overall sentiment is mixed, with concerns about a potential reverse split and the impact of AI hype on the sector.

CEA Industries, Inc. engages in in the development, design, and distribution of cultivation technologies for controlled environment agriculture, primarily for cannabis crops. It offers controlled climate systems, controls, and biosecurity cultivation products, and MEP engineering, odor control, and installation support services. The company was founded by Brandy Marie Keen and Stephen Keen on October 15, 2009 and is headquartered in Louisville, CO.

CEA Industries Inc

CEA Industries Inc ($BNC) is trending due to discussions around a potential short squeeze, driven by high short interest and a low float, with some noting difficulty buying shares through certain brokers. The community is also analyzing the company's recent shift towards building a significant BNB treasury, drawing comparisons to other crypto-related stocks. Some traders are expressing frustration with the stock's performance despite positive developments in the underlying BNB asset.

Darden Restaurants, Inc. is a full-service restaurant company, which engages in the provision of restaurant services. It operates through the following segments: Olive Garden, LongHorn Steakhouse, Fine Dining, and Other Business. The Olive Garden segment is the largest full-service dining Italian restaurant operator. The LongHorn Steakhouse segment includes the results of the company-owned LongHorn Steakhouse restaurants. The Fine Dining segment consists of the premium brands that operate within the fine-dining sub-segment of full-service dining and includes the results of its company-owned The Capital Grille and Eddie V's restaurants. The Other Business segment aggregates the remaining brands and includes the results of its company-owned Cheddar's Scratch Kitchen, Yard House, Seasons 52 and Bahama Breeze restaurants, and from franchises and consumer-packaged goods sales. The company was founded by William B. Darden in 1938 and is headquartered in Orlando, FL.

Darden Restaurants, Inc.

Darden Restaurants ($DRI) is trending amid mixed reactions to recent earnings and revenue figures, with some analysts anticipating price target increases. Community discussions highlight momentum traders observing strong tape action and potential range expansion, while others focus on short positions around a key price level. The broader context includes potential catalysts from clean tech initiatives and utility pilot markets.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR.X is trending as the community anticipates a breakout, fueled by discussions around AI integration and potential for new all-time highs. Positive sentiment is building, with many highlighting its undervalued status and setting price targets, while some traders pointing out its lack of momentum compared to other altcoins. Recent news around cross-chain capabilities and validator voting on inflation are also being closely watched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's  What You Should Know

The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough Trevi Therapeutics Completes Enrollment for Phase 2b CORAL...

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Trevi Therapeutics to Participate in Upcoming February Investor Conferences Trevi Therapeutics to Participate in Upcoming February Investor Conferences PR Newswire NEW HAVEN, Conn., Jan. 30, 2025 NEW...

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Trevi Therapeutics Announces Company...

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering PR Newswire NEW HAVEN, Conn., Dec. 16, 2024 NEW...

Shares of Trevi Therapeutics Inc. rose over 6% on Friday morning, building on momentum from the previous session when the stock hit over two-year intraday highs.&nbsp;The surge came as heavy retail buzz pushed the ticker to prominence on Stocktwits, where message volume spiked over 4,900% on Thursday.The company announced that its phase 2b study of Haduvio, an investigational therapy for idiopathic pulmonary fibrosis (IPF) with chronic cough, has achieved 75% of its enrollment target of 160 patients.&nbsp;An independent statistician confirmed the sample size following a re-estimation analysis, ensuring the trial’s design remains statistically robust.&nbsp;The analysis involved treating 80 patients with Haduvio’s highest dose (108 mg twice daily) over six weeks.Trevi reiterated that topline results are expected in the first half of 2025.Wall Street analysts responded positively to the update:•&nbsp;Jones Research reiterated a ‘Buy’ rating, stating the analysis enhances confidence in the trial’s statistical assumptions, which indicate a high likelihood of demonstrating significant cough reduction.• Needham’s Serge Belanger called the result the “best case outcome,” highlighting it as a de-risking event.&nbsp;He highlighted that&nbsp;the study’s treatment effect size and dropout rates align with initial assumptions, supporting the original design. Needham maintained a ‘Buy’ rating with an $8 price target.• H.C. Wainwright raised its price target to $7.50 from $6, describing the update as a “material positive” for investor sentiment ahead of data readouts.Year-to-date, TRVI stock has gained over 170%, as of the last close,&nbsp; showcasing strong investor interest in the company’s pipeline and prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75%

An independent statistician confirmed the sample size following a re-estimation analysis, ensuring that the trial’s design remains statistically robust.

Equity

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients...

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of...

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference PR Newswire NEW HAVEN, Conn...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Trevi Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$8.54
Prev Close	$7.98
Open	$8.03
Dividend Yield	0.00%
50-Day Moving Average	$7.46
Beta	0.73
Avg. Volume	1.88M
PE Ratio	-18.97

52-Week High	$9.92
52-Week Low	$2.36
Market Capitalization	$971.78M
EPS (Annual)	-$0.4698
Price to Book	4.90
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TRVI
Trevi Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRVI News

TRVI Trevi Therapeutics Inc